StockData

Autolus Therapeutics vs Mesoblast

AUTL and MESO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

autlAutolus Therapeutics$1.17−14.0% in 1 yearmesoMesoblast$13.27−15.5% in 1 year

How AUTL and MESO compare

Mesoblast grew revenue faster over the last twelve months (599% versus 169% for Autolus Therapeutics).

Mesoblast keeps more of each dollar of sales as profit, with a net margin of −47.8% compared with −186% at Autolus Therapeutics.

Mesoblast scores higher on the StockData Score (6 against 4 for Autolus Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAUTLMESO
Size and price
Market cap$311M–
Share price$1.17$13.27
Change, 1 year−14.0%−15.5%
Change, 5 years−81.2%6.3%
Beta (5Y)1.841.50
Employees754108
StockData Score
Total score46 (better)
Valuation score00
Growth score33
Performance score02 (better)
Health score11
Dividend score00
Valuation
P/S2.3×–
P/B11.4×–
FCF yield−57.9%–
Growth
Revenue growth (TTM)169%599% (better)
Revenue growth, 5Y average–74.5%
Profitability
Gross margin35.8%86.1% (better)
Operating margin−160%–
Net margin−186%−47.8% (better)
FCF margin−131%−37.1% (better)
Return on equity−175%–
Financial health
Interest coverage−4.8×–
Current ratio3.72 (better)2.43
Altman Z-score−4.28–
Piotroski F-score25 (better)
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions49.7%0.30%
Held by insiders24.6%37.3%
Insider net buying, 12 months−$15.7K$37.5M (better)

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.